Enrolling By InvitationNCT03338387
Co-Feedback Action of Growth Hormone, PP and PYY on Ghrelin in Bulimia
Medication studyAges 18–30Eating disorders
Understand this study
Who could participate?
Listed age limits: 18 years to 30 years.
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: May 6, 2003
- Recruitment status
- Enrolling By Invitation
- Enrollment listed in the registry
- 24
- Sponsor
- Charles University, Czech Republic
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Not clearly listed
- Age range
- From 18 Years to 30 Years
- Official registry ID
- NCT03338387
- Official title
Show the full official title
Acipimox Administration Together With Short-Term Exercise Exerts A Co-Feedback of Growth Hormone, Pancreatic Polypeptide, Peptide YY and Leptin on Ghrelin in Young Bulimic Czech Women: A Randomized Study
Recruitment & locations
By invitationThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Locations not listed
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Charles University, Czech Republic, a university.
Does this study involve medication?
Yes. The study involves medication, including Acipimox and Placebo.
Who can participate?
Listed age limits: 18 years to 30 years.
Is this study still recruiting?
The registry lists this study as enrolling by invitation.
